Effect of the dopamine stabilizer (-)-OSU6162 on potentiated incubation of opioid craving after electric barrier-induced voluntary abstinence

• Published in: Neuropsychopharmacology (New York, N.Y.) N.Y.), 2020-04, Vol.45 (5), p.770-779
• Main Authors: Fredriksson, Ida, Applebey, Sarah V, Minier-Toribio, Angelica, Shekara, Aniruddha, Bossert, Jennifer M, Shaham, Yavin
• Format: Article
• Language: English
• Subjects: Abstinence; Animals; Behavior, Animal - drug effects; Craving - drug effects; Dopamine; Dopamine - physiology; Drug addiction; Drug therapy; Drug-Seeking Behavior - drug effects; Electroshock; Female; Male; Narcotics; Opioids; Oxycodone; Oxycodone - administration & dosage; Piperidines - administration & dosage; Punishment; Rats, Sprague-Dawley; Recurrence; Rodents; Self-administration
• ISSN: 0893-133X; 1740-634X; 1740-634X
• DOI: 10.1038/s41386-020-0602-6

In the classical incubation of drug craving rat model, drug seeking is assessed after homecage forced abstinence. However, human abstinence is often voluntary because negative consequences of drug seeking outweigh the desire for the drug. Here, we developed a rat model of incubation of opioid craving after electric barrier-induced voluntary abstinence and determined whether the dopamine stabilizer (-)-OSU6162 would decrease this new form of incubation. We trained male and female rats to self-administer oxycodone (0.1 mg/kg/infusion, 6 h/day) for 14 days. We then exposed them to either homecage forced abstinence or voluntary abstinence induced by an electric barrier of increasing intensity near the drug-paired lever. On abstinence days 1, 15, or 30, we tested the rats for oxycodone seeking without shock and drug. We also examined the effect of (-)-OSU6162 (7.5 and 15 mg/kg) on oxycodone seeking on abstinence day 1 or after 15 days of either voluntary or forced abstinence. Independent of sex, the time-dependent increase in oxycodone seeking after cessation of opioid self-administration (incubation of opioid craving) was stronger after voluntary abstinence than after forced abstinence. In males, (-)-OSU6162 decreased incubated (day 15) but not non-incubated (day 1) oxycodone seeking after either voluntary or forced abstinence. In females, (-)-OSU6162 modestly decreased incubated oxycodone seeking after voluntary but not forced abstinence. Results suggest that voluntary abstinence induced by negative consequences of drug seeking can paradoxically potentiate opioid craving and relapse. We propose the dopamine stabilizer (-)-OSU6162 may serve as an adjunct pharmacological treatment to prevent relapse in male opioid users.